Université de Paris, Inserm U1153, Epidemiology of Ageing and Neurodegenerative Diseases, Paris, France.
Department of Epidemiology and Public Health, University College London, London, UK.
Alzheimers Res Ther. 2021 Jan 4;13(1):5. doi: 10.1186/s13195-020-00740-0.
Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life course remains uncertain. This study aims to examine whether the association between Apolipoprotein E (APOE) ε4 zygosity and cognition function is modified between midlife and old age.
A cohort study of 5561 participants (mean age 55.5 (SD = 5.9) years, 27.1% women) with APOE genotyping and repeated cognitive tests for reasoning, memory, and semantic and phonemic fluency, during a mean (SD) follow-up of 20.2 (2.8) years (the Whitehall II study). We used joint models to examine the association of APOE genotype with cognitive function trajectories between 45 and 85 years taking drop-out, dementia, and death into account and Fine and Gray models to examine associations with dementia.
Compared to non-carriers, heterozygote (prevalence 25%) and homozygote (prevalence 2%) APOE ε4 carriers had increased risk of dementia, sub-distribution hazard ratios 2.19 (95% CI 1.73, 2.77) and 5.97 (95% CI 3.85, 9.28) respectively. Using data spanning 45-85 years with non-ε4 carriers as the reference, ε4 homozygotes had poorer global cognitive score starting from 65 years; ε4 heterozygotes had better scores between 45 and 55 years, then no difference until poorer cognitive scores from 75 years onwards. In analysis of individual cognitive tests, better cognitive performance in the younger ε4 heterozygotes was primarily attributable to executive function.
Both heterozygous and homozygous ε4 carriers had poorer cognition and greater risk of dementia at older ages. Our findings show some support for a complex antagonist pleiotropic effect of APOE ε4 heterozygosity over the adult life course, characterized by cognitive advantage in midlife.
大约 25%的普通人群携带载脂蛋白 E(APOE)ε4 至少一个等位基因,这是阿尔茨海默病发病晚的最强遗传风险因素。除了与发病晚的痴呆症相关外,APOE ε4 与成年期认知功能变化之间的关联仍然不确定。本研究旨在检验 Apolipoprotein E(APOE)ε4 基因型与认知功能之间的关联是否在中年和老年之间发生变化。
一项队列研究纳入了 5561 名参与者(平均年龄 55.5(SD=5.9)岁,27.1%为女性),他们进行了 APOE 基因分型和推理、记忆、语义和语音流畅性的重复认知测试,平均(SD)随访时间为 20.2(2.8)年(Whitehall II 研究)。我们使用联合模型来研究 APOE 基因型与 45 至 85 岁之间的认知功能轨迹之间的关联,同时考虑了辍学、痴呆和死亡,使用 Fine 和 Gray 模型来研究与痴呆的关联。
与非携带者相比,杂合子(患病率为 25%)和纯合子(患病率为 2%)APOE ε4 携带者患痴呆的风险增加,亚分布风险比分别为 2.19(95%CI 1.73, 2.77)和 5.97(95%CI 3.85, 9.28)。使用非 ε4 携带者在 45-85 岁之间的数据作为参考,ε4 纯合子从 65 岁开始认知总分较差;ε4 杂合子在 45 至 55 岁之间得分较高,然后直到 75 岁以后认知得分较差时才没有差异。在对个别认知测试的分析中,年轻的 ε4 杂合子认知表现较好主要归因于执行功能。
杂合子和纯合子 ε4 携带者在年龄较大时认知功能较差,痴呆风险增加。我们的研究结果表明,APOE ε4 杂合子在成年期具有复杂的拮抗多效性效应,在中年具有认知优势,这一假说得到了一些支持。